FGFR1 and adenocarcinoma: In lung cancer, FGFR1 has been found amplified in about 6% of patients classified either as SCLC or NSCLC, and FGFR1 amplifications are predominant (~17%) in patients with SCC followed by SCLC (~6%) and adenocarcinoma (~1%) [11,12,13].